



Fondazione IRCCS
Policlinico San Matteo di Pavia



Università degli Studi di Pavia
Scuola di Specializzazione
in Oncologia Medica

Kidney Cancer Association
www.KidneyCancer.org

Second Pavia International Symposium on Advanced Kidney Cancer

The 3rd Perugia-Pavia post-ASCO
Kidney Cancer meeting

Università degli Studi di Pavia
Aula del '400

June 26-27, 2009

programma preliminare
preliminary program





Fondazione IRCCS Policlinico San Matteo
Pavia

Presidente:

CAMILLO PORTA

Fondazione IRCCS Policlinico San Matteo - Pavia

Co-Presidente:

SERGIO BRACARDA

Ospedale S. Maria della Misericordia, Azienda Ospedaliera di Perugia

Segreteria Scientifica:

CHIARA PAGLINO

ILARIA IMARISIO

Oncologia Medica - Fondazione IRCCS Policlinico San Matteo - Pavia

Segreteria Organizzativa:

START PROMOTION srl

Via Mauro Macchi, 50 - 20124 Milano

Tel. 02-67071383 - Fax 02-67072294

E-mail: info@startpromotion.it

www.startpromotion.it

Faculty

Bearz A. Aviano (Pordenone)
Bianco R. Napoli
Biganzoli E. Milano
Bracarda S. Perugia
Bukowski R.M. Cleveland (USA)
Caccialanza R. Pavia
Calabrò F. Roma
Carteni G. Napoli
Caserta C. Terni
Ceresoli G.L. Rozzano (Milano)
Choueiri T.K. Cleveland (USA)
Cognetti F. Roma
Cruciani G. Ravenna
Danova M. Pavia
Dutcher J.P. New York (USA)
Escudier B. Paris (F)
Ficarra V. Padova
Fornarini G. Genova
Galligioni E. Trento
Imarisio I. Pavia
Landi L. Livorno
Larkin J.M.G. London (UK)
Moroni M. Milano
Naglieri E. Bari
Ortega C. Torino
Paglino C. Pavia
Porta C. Pavia
Procopio G. Milano
Rovereto B. Pavia
Riccardi A. Pavia
Rini B. Cleveland (USA)
Ruggeri E.M. Viterbo
Schmidinger M. Wien (A)
Sternberg C. Roma
Szczylik C. Warsaw (PL)
Zucali P. Rozzano (Milano)

9.15 Welcome from the Authorities
9.30 Opening remarks

Keynote Lecture

CHAIRPERSONS: C. Porta, C. Ortega

9.45 Treatment algorithm for advanced kidney cancer patients in 2009
B. Rini

10.15 Discussion

10.20 *Coffee break*

Controversial

CHAIRPERSONS: G. Procopio, R. Bukowski

10.35 Clinical or molecular prognostic/predictive factors to guide treatment choices in kidney cancer
Clinical – E. Naglieri
Molecular – T. Choueiri

11.30 Discussion

Controversial

CHAIRPERSONS: B. Rini, C. Porta

11.35 Which is the optimal first line treatment for advanced kidney cancer?
• Sunitinib – J. Dutcher
• Bevacizumab plus Interferon – B. Escudier

12.30 Discussion

Controversial

CHAIRPERSONS: B. Rovereto, G.L. Ceresoli

12.35 Advanced kidney cancer in the era of targeted agents: is there still a role for palliative nephrectomy?
• Pro – V. Ficarra
• Contra – C.Ortega

13.30 Discussion

13.35 *Lunch*

Keynote lecture

CHAIRPERSONS: C. Szczylik, P. Zucali

15.05 Is there still a role for cytokines in the present management strategy for advanced kidney cancer?
E. Galligioni

15.35 Discussion

Keynote lecture

CHAIRPERSONS: C. Ortega, G. Procopio

15.40 Patient-focused treatment approach to advanced kidney cancer: how to place Sorafenib in the present treatment algorithm
C. Szczylik

16.10 Discussion

16.15 *Coffee break*

Peter De Mulder Memorial Prize

CHAIRPERSONS: L. Landi, C. Paglino

16.30 Peter De Mulder Memorial Prize to the best scientific contribution from a Young Investigator

17.00 Presentation of the Re.Na.Ca.Re. (Registro Italiano Carcinoma Renale - Italian Registry for Renal Cell Cancer) initiative
C. Porta

17.30 Discussion



Keynote lecture

CHAIRPERSONS: *A. Riccardi, M. Danova*

- 9.15 Temsirolimus: an option just for poor-risk patients, or something more?
G. Procopio
- 9.45 Discussion

SCIENTIFIC SYMPOSIUM

Understanding and managing the toxicities from molecularly targeted agents for advanced kidney cancer

CHAIRPERSONS: *G. Cruciani, G. Procopio*

- 9.50 Cardiac toxicity from molecularly-targeted agents
M. Schmidinger
- 10.10 Thyroid and metabolic side-effects from molecularly targeted agents (TKIs and mTOR inhibitors)
G. Carteni
- 10.30 Dermatological toxicity
A. Bearz
- 10.50 The management of the anorexia/cachexia syndrome in advanced kidney cancer patients
R. Caccialanza
- 11.10 Discussion
- 11.20 *Coffee break*
- 11.35 **Poster viewing**

CHAIRPERSONS: *I. Imarisio, C. Caserta*

SCIENTIFIC SYMPOSIUM

Next challenges

CHAIRPERSONS: *E.M. Ruggeri, M. Moroni*

- 11.50 Understanding the mechanism of resistance to TKIs and mTOR inhibitors
R. Bianco
- 12.10 Horizontal and vertical blockade
F. Calabrò
- 12.30 Discussion
- 12.40 *Lunch*

Controversial

CHAIRPERSONS: *B. Escudier, F. Cognetti*

- 14.05 Which is the optimal second line treatment for advanced kidney cancer?
 - Sequencing TKIs – *C. Sternberg*
 - Everolimus – *J.M.G. Larkin*
- 14.55 Discussion

Controversial

CHAIRPERSONS: *M. Schmidinger, C. Szczylik*

- 15.05 Multikinase inhibitors and cytokines: to combine or not?
 - Pro – *S. Bracarda*
 - Contra – *C. Porta*
- 15.55 Discussion
- 16.05 *Coffee break*



► **SCIENTIFIC SYMPOSIUM**

**Understanding the results of clinical trials:
focusing on different end-points**

CHAIRPERSONS: P. Zucali, G. Fornarini

- 16.20 The Oncologist's viewpoint
S. Bracarda
- 16.40 The statistician's viewpoint
E. Biganzoli
- 17.00 Discussion

► **Keynote lecture**

CHAIRPERSONS: B. Escudier, C. Porta

- 17.10 Medical treatment of kidney cancer in the next decade: where
are we going?
R. Bukowski
- 17.40 Closing remarks

*On the occasion of the **Second Pavia International Symposium**, a scientific contest will take place to select the best paper on whatever aspect of the research (either experimental or clinical) on kidney cancer, presented by a young researcher (age <40 years). The winner will be awarded a cheque of € 2.000. **This prize is dedicated to the memory of the late Professor Pieter De Mulder, who died because of that tumour he had been fighting for years.***

*The abstracts must be sent, **within May 10th 2009**, to the Scientific Secretary of the Symposium, as Word documents written in English not exceeding 2500 characters (spaces included).*

The Author of the best paper will be awarded the De Mulder prize and entitled to present his/her work as oral presentation during the Symposium.

All the other papers will be presented in poster format.

All the abstracts received will be published in a Supplement to Oncology Review.



Sede del Convegno

Università degli Studi
di Pavia
Aula del '400
P.zza Leonardo da Vinci
27100 Pavia



Iscrizione

Il Convegno è a numero chiuso ed è riservato ad un massimo di 200 partecipanti. Oltre questo numero non si accettano ulteriori iscrizioni.

Kidney Cancer Association

L'Associazione (KCA) è una organizzazione caritatevole fatto di pazienti, familiari, medici, ricercatori e altri professionisti della salute a livello globale che collabora con il National Cancer Institute (NCI), American Society for Clinical Oncology (ASCO), American urologici Association (AUA), e altre istituzioni su progetti di ricerca.

L'Associazione è stata fondata nel 1990 da un piccolo gruppo di pazienti e medici a Chicago. Si tratta di una associazione Onlus costituita nello Stato dell'Illinois. Si richiederà in loco ai partecipanti, di supportare l'Associazione con una donazione.

ECM

Per il Convegno è stato richiesto l'accREDITAMENTO ECM presso il Ministero della Salute per la seguente figura professionale:

- Medico (discipline di riferimento: oncologia; radioterapia; urologia).

Patrocinii richiesti:



Associazione Italiana
di Oncologia Medica



Società Italiana
di Urologia Oncologica



Provincia di Pavia



Comune di Pavia



In collaborazione con:



Bayer HealthCare
Bayer Schering Pharma



Wyeth

